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Abstract 
Background 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer with 
approximately half a million cases diagnosed each year worldwide. HNSCC has a poor 
survival rate which has not improved for over 30 years. The molecular pathogenesis of 
HNSCCs remains largely unresolved; there is high prevalence of p53 mutations and EGFR 
overexpression, however the contribution of these molecular changes to disease 
development and/or progression remains unknown. We have recently identified microRNA 
miR-196a to be highly overexpressed in HNSCC with poor prognosis. Oncogenic miR-196a 
directly targets Annexin A1 (ANXA1). Although increased ANXA1 expression levels have 
*Manuscript
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been associated with breast cancer development, its role in HNSCC is debatable and its 
functional contribution to HNSCC development remains unclear.  
Methods 
ANXA1 mRNA and protein expression levels were determined by RNA Seq analysis and 
immunohistochemistry, respectively. Gain- and loss-of-function studies were performed to 
analyse the effects of ANXA1 modulation on cell proliferation, mechanism of activation of 
EGFR signalling as well as on exosome production and exosomal phospho-EGFR. 
Results 
ANXA1 was found to be downregulated in head and neck cancer tissues, both at mRNA and 
protein level. Its anti-proliferative effects were mediated through the intracellular form of the 
protein. Importantly, ANXA1 downregulation resulted in phosphorylation and activity of EGFR 
and its downstream PI3K-AKT signalling. Additionally, ANXA1 modulation affected exosome 
production and influenced the release of exosomal phospho-EGFR. 
Conclusions 
ANXA1 acts as a tumour suppressor in HNSCC. It is involved in the regulation of EGFR 
activity and exosomal phospho-EGFR release and could be an important prognostic 
biomarker. 
 
Highlights 
 Annexin A1 (ANXA1) protein levels are significantly downregulated in head and neck 
cancer cell lines and tumour samples. 
 Annexin A1 acts as a potential tumour suppressor in head and neck cancer. 
 The tumour suppressive activities are mainly mediated by the intracellular rather than 
the secreted form of ANXA1. 
 ANXA1 downregulation results in increased epidermal growth factor receptor (EGFR) 
tyrosine 1068 phosphorylation and AKT activity in the presence of recombinant EGF. 
 ANXA1 regulates exosome production and release of exosomal phospho-EGFR. 
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Introduction 
Every year nearly 600,000 new cases of head and neck cancer are diagnosed worldwide 
which equals over 1451 cases every day [1]. Incidence rates are rising and most patients 
present with advanced stages of the disease which negatively impacts treatment success [1, 
2]. Additionally, the molecular pathways involved in the development and progression of 
head and neck squamous cell carcinomas (HNSCC) remain largely unknown. Therefore, 
there is an important need to identify predictive and prognostic biomarkers and understand 
their functional contribution to HNSCC development. We recently identified Annexin A1 
(ANXA1) as a target of the oncogenic microRNA miR-196a [3]. The 37 kDa ANXA1 (also 
known as lipocortin-1) is a member of the annexin superfamily of proteins, which contains 
multiple calcium and phospholipid-binding proteins implicated in a broad range of cellular 
functions [4, 5]. ANXA1 exists in two major forms – a secreted extracellular (cleaved) protein 
and a full-length intracellular protein [6]. Originally, ANXA1 was identified as a 
glucocorticoid-regulated anti-inflammatory protein with important functions in the innate and 
adaptive immune response [7]. These activities were mainly attributed to the externalized 
form of ANXA1 and are mediated by binding of the protein to formyl peptide receptors 
(FPRs), seven transmembrane domain, G protein coupled receptors [7]. In contrast to the 
mainly anti-inflammatory functions of secreted ANXA1, the full-length intracellular protein has 
been associated with a wide range of cellular functions such as cytoskeletal organization, 
plasma membrane repair, autophagy and intracellular calcium signalling as well as lipid 
mediated signalling pathways [8-11]. Different intracellular localizations and stimulus- or 
modification-dependent redistributions of the ANXA1 protein have been observed [12, 13]. A 
role of ANXA1 in tumour development and progression has been described for different 
cancer subtypes. While in most cancer types such as breast, cervical, hepatic and pancreatic 
cancer high levels of ANXA1 have been associated with more aggressive disease, its role in 
HNSCC remains debatable [14-19]. Interestingly, one of the main risk factors of oral cancer, 
chewing tobacco, results in the loss of the anti-inflammatory activity of ANXA1 rather than its 
increase [20]. 
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In recent years, ANXA1 has been linked to epidermal growth-factor receptor signalling in 
cervical cancer [21]. Epidermal growth factor receptor (EGFR), also known as Her1 or 
ErbB-1, is a receptor tyrosine kinase belonging to the ErbB family of receptors which also 
includes ErbB-2, ErbB-3 and ErbB-4 [22]. EGFR is widely considered to be one of the central 
drivers of oncogenesis in HNSCC [23]. More than 80% of HNSCC cases exhibit an increased 
membraneous expression of EGFR and overexpression of the receptor is linked to 
radiotherapy-resistance mechanisms [24, 25]. Natural ligands of EGFR are growth factors, 
including EGF and TGF- [26, 27]. Ligand binding results in receptor phosphorylation and 
activation, although ligand-independent and constitutive EGFR signalling have also been 
described [28, 29]. EGFR activation steers among others JAK/STAT signalling as well as the 
PI3K/AKT, the RAS/RAF/ERK and the PLC/PKC pathways controlling processes including 
DNA repair, proliferation, angiogenesis, and inhibition of apoptosis [30]. Several EGFR-
targeting drugs have been developed. One if these drugs is cetuximab, an IgG1 chimerized 
EGFR monoclonal antibody with high affinity for the extracellular EGF domain of EGFR and 
thereby preventing ligand binding and receptor activation [31]. However, EGFR targeted 
drugs so far have shown very limited effect in HNSCC.  
Depending on the type of ligand, ligand-activated EGFR can signal from various subcellular 
compartments unless it is sequestered on intraluminal vesicles (ILVs) in the lumen of 
multivesicular endosomes where it is delivered to lysosomes for degradation [32]. ANXA1 
has been suggested to be important for the formation of the intraluminal vesicles and thus 
termination of EGFR signalling in cervical cancer [33, 34]. ILVs are also precursors of a type 
of extracellular vesicles called exosomes [35]. Interestingly, in addition to its intracellular 
function, lately, a role of extracellular exosomal EGFR in metastasis formation and tumour 
immunity has been described [36, 37]. In this study we have investigated the involvement of 
ANXA1 in HNSCC with the aim of exploiting its potential as a prognostic/predictive biomarker 
and/or therapeutic target in the cancers of head and neck.  
 
 
Materials and Methods 
Cell lines and tissue culture 
The cell lines included in this study were HEK293T cells, the head and neck squamous cell 
carcinoma (HNSCC) cell lines HN5, HN30, HSC3, H357, UTSCC-34, UTSCC-6A, SCC-22B 
as well as the breast cancer cell line MCF-7. UTSCC-34 and UTSCC-6A cells were provided 
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by Professor Reidar Grenman, Department of Otorhinolaryngology, Head and Neck Surgery, 
Turku University and Turku University Hospital, Turku, Finland, SCC-22B cells by Dr Thomas 
Carey, University of Michigan, USA, and H357 cells by Dr Stephen Prime, Department of 
Oral and Dental Science, University of Bristol, Bristol, UK. HN5 and HSC3 cells were 
obtained from Professor Barry Gusterson, Department of Pathology, University of Glasgow, 
UK and Dr Kazuya Tominaga, Department of Oral Pathology, Osaka Dental University, 
Japan, respectively. HN30 cells were provided by Dr Andrew Yeudall, Philips Institute of Oral 
and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, 
USA. HEK293T cells which were used for retro- and lentivirus production were a gift from Dr. 
Lucas Chan, Rayne Institute, King’s College London, UK. All cell lines except H357, 
UTSCC-34 and UTSCC-6A were maintained in Dulbecco’s Modified Eagles Medium (DMEM; 
GE Healthcare, Chalfont St. Giles, UK) supplemented with 10% fetal bovine serum (FBS), 
50 µg/ml streptomycin, 100 µg/ml penicillin and 1 mM sodium pyruvate. UTSCC-34 and 
UTSCC-6A cells were maintained in DMEM (GE Healthcare, Chalfont St. Giles, UK) 
supplemented with 10% FBS, 2 mM L-glutamine, 5 ml nonessential amino acids, 125 µg/ml 
streptomycin and 250 µg/ml penicillin. For H357 cells DMEM-F12 supplemented with 10% 
FBS, 4 mM L-glutamine, 69 nM hydrocortisone, 50 µg/ml streptomycin, 100 µg/ml penicillin 
and 1 mM sodium pyruvate was used. Expression of ANXA1 was stably modulated in 
selected HNSCC cell lines. Lentiviral constructs used for downregulation of ANXA1 have 
been described previously [3]. Sh-scrambled control and sh-ANXA1 expressing cells were 
selected using 2 µg/ml puromycin. For treatment with recombinant EGF (Peprotech, London, 
UK), 500 000 cells per well were seeded in a 6-well plate. The next day, cells were serum-
starved and 24h later treated with 50 – 200 ng/ml recombinant EGF (in 5% trehalose) or 5% 
trehalose only for the indicated time points. For cellular proliferation studies with recombinant 
ANXA1, 100 nM recombinant ANXA1 were included. Recombinant ANXA1 was provided by 
Prof Mauro Perretti, William Harvey Research Institute, Barts and The London School of 
Medicine, Queen Mary University of London, UK. pLenti-puro-hANXA1-FL was a kind gift 
from Dr. Egle Solito, William Harvey Research Institute, Barts and the London School of 
Medicine and Dentistry, Queen Mary University of London, UK. 
 
Western blot analysis 
Immunoblotting was performed as described previously [38]. Briefly, cells were lysed in lysis 
buffer (1 mM MgCl2, 12.5 mM HEPES/KOH, pH 7.4, 1 mM EGTA, 1% Triton-X100) or 10x 
RIPA buffer (exosomes) including protease inhibitors. Protein concentration was determined 
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by Bradford assay and 25 to 50 µg of protein was separated on 8-15% 1.5 mm thick 
SDS-gels and transferred to nitrocellulose membranes (400 mA, 90 min) using the 
Mini-PROTEAN electrophoresis system combined with the Mini-Trans Blot module (Bio-Rad, 
Hercules, CA, USA). Afterwards membranes were probed with the antibodies of choice. 
Antibodies used for immunoblotting were: beta-actin, alpha-tubulin (Sigma-Aldrich, St. Louis, 
MO, USA), EGFR F4, phospho-ERK1/2, phospho-AKT (Ser473) phospho-EGFR (Tyr1068), 
pan-AKT, phospho-STAT3 (Tyr705), pan-STAT3, ANXA1 (Cell Signaling, Danvers, MA, 
USA) and CD63 (MEM-259, GeneTex, Inc., Irvine, CA, USA). Antibodies were used at a 
concentration of 1:1000 or 1:5000 (beta-actin, alpha-tubulin). Secondary HRP-coupled 
anti-rabbit (1:2000) and anti-mouse antibodies (1:1000) were obtained from Fisher Scientific 
(Loughborough, UK) and Sigma-Aldrich (St. Louis, MO, USA), respectively. 
 
Immunofluorescence 
30 000 cells were seeded in duplicate in 8-chamber slides (BD Biosciences, San Jose, CA, 
USA). The next day, cells were washed twice with 1x PBS and fixed in 4% paraformaldehyde 
for 15 min. Following 2 washing step with 1x PBS, cells were permeabilised for 15 min using 
0.2% Triton-X100, then washed again and incubated for 30 min in 3% bovine serum albumin 
(BSA) in TBS-Tween. Cells were incubated at 4°C overnight under constant agitation in 
antibodies of choice (diluted in 3% BSA in TBS-Tween) or 3% BSA in TBS-Tween only as 
negative control. Afterwards, cells were washed twice using 1x PBS and then incubated with 
secondary fluorescently tagged antibody for 90 min at 37°C protected from light. Following 
several washing steps in 1x PBS, the chambers were removed from the slides and cells were 
mounted in Vectashield mounting medium containing 4’,6-diamidin-2-phenylindole (DAPI; 
Vector Laboratories; Burlingame, CA, USA). Images were acquired on an Olympus BX61 at 
60x magnification. Antibodies used for immunofluorescence were: EGFR F4, FPR2. The 
FPR2 antibody was kindly provided by Prof Mauro Perretti, William Harvey Research 
Institute, Barts and The London School of Medicine, Queen Mary University of London, UK. 
 
Lentiviral based expression modulation 
ANXA1 knockdown and scrambled control cells were generated as described previously [3]. 
Virus was produced in HEK293T cells. Viral supernatant was harvested after 24, 36 and 48h, 
filtered through a 0.45 µm filter and immediately used for transduction of target cells. Cells 
were selected based on their newly acquired antibiotic resistance.  
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Cell proliferation assay 
30 000 cells per well were seeded in triplicate in 6-well plates. Over the following 5 days, 
cells were trypsinized and counted using a Neubauer chamber. Cell proliferation was also 
assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell 
viability assay. Stably modulated cells were seeded in a 96-well plate (2000 cells in 150 µl 
medium per well), 6 wells per time point. The next day, the medium was replaced with 150 µl 
DMEM +/- 100 nM recombinant ANXA1 or different concentrations of recombinant EGF (0.5, 
5 and 50 ng/ml) using trehalose as vehicle control. The following 5 days, 20 µl MTT solution 
(Calbiochem, Watford, UK; 5 mg/ml MTT in 1x PBS) was added to each well and after 2h of 
incubation 150 µl solubilisation solution (50% dimethylformamide, 0.2% glacial acetic acid, 
20 mM HCl, 20% SDS) was added. After incubation over night, the OD595nm was measured 
on a Tecan Infinite F50. Medium +/- 100 nM recombinant ANXA1 or recombinant EGF was 
renewed daily over the course of the experiment.  
 
Cell viability assay (cetuximab) 
Cells were seeded in 96-well plates at a density of 6000 cells per well. The next day, cells 
were treated with cetuximab (Erbitux®, Merck KGaA, Darmstadt, Germany) and cell viability 
was assessed after the indicated time points by adding 20 µl of MTT solution and, after 1-2h 
of incubation, 150 µl of solubilisation solution to each well. Following overnight incubation, 
OD595nm was measured using a Tecan Infinite F50. 
 
RNA Seq 
Publicly available RNA sequencing data from The Cancer Genome Atlas (TCGA) was used 
(GSE62944) to compare ANXA1 gene expression (FPKM values) between healthy and 
tumour samples from 13 different tissues [39]. The following tissues were used for the study: 
Tissue Healthy (total) Tumour (total) 
Bladder Urothelial Carcinoma (BLCA) 19 414 
Breast Invasive Carcinoma (BRCA) 113 1119 
Colon Adenocarcinoma (COAD) 41 483 
Glioblastoma Multiforme (GBM) 5 170 
Head and Neck Squamous Carcinoma 44 504 
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(HNSC) 
Kidney Renal Clear Cell Carcinoma (KIRC) 72 542 
Kidney Renal Papillary Cell Carcinoma 
(KIRP) 
32 291 
Liver Hepatocellular Carcinoma (LIHC) 50 374 
Lung Adenocarcinoma (LUAD) 59 541 
Lung Squamous Cell Carcinoma (LUSC) 51 502 
Prostate Adenocarcinoma (PRAD) 52 502 
Stomach Adenocarcinoma (STAD) 37 420 
Uterine Corpus Endometrial Carcinoma 
(UCEC) 
35 554 
 
The processed FPKM values from healthy and tumour tissues were log2 transformed and 
implemented to the Linear Models for Microarray Data (limma) for differential expression 
analysis [40]. The limma-trend method was used by inputting the log2-FPKM values into 
limma’s standard pipeline, with trend=TRUE for the empirical Bayes function. limma uses an 
eBayes t-test that takes into account the global variance to minimize the influence of noise of 
local variance for small samples. 
 
Immunohistochemistry 
Immunohistochemical staining on head and neck cancer tissue samples was previously 
approved by the UK National Research Ethics Service (Reference: 10/H0701/27). Forty-one 
consecutive patients with oropharyngeal squamous cell carcinoma were retrospectively 
identified from pathology databases. Following review by a specialist head and neck 
pathologist, 4 µm paraffin sections were routinely prepared. ANXA1 (Clone MRQ-3), EGFR 
extracellular domain (Clone 3C6) and EGFR intracellular domain (Clone 5B7) 
immunohistochemical staining was undertaken using prediluted proprietary kit (Clone 
MRQ-3, Ventana Medical Systems) on a Ventana Benchmark Autostainer (Ventana Medical 
Systems) according to manufacturer instructions. Oral squamous cell carcinoma and splenic 
hairy cell leukaemia were used as positive controls for EGFR and ANXA1, respectively. 
Omission of the primary antibody served as negative controls.  
All cases were independently scored by at least two observers. Where present, the 
non-dysplastic surface or reticulated crypt epithelium was taken as the referent. An ordinate 
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value of 0-3 was assigned to the intensity of nuclear staining. The percentage of each 
intensity was allotted to the entire tumour within the whole mount tissue section and a 
product of each intensity value and its percentage stained within the tumour was determined. 
A nuclear ‘H-Score’ was then determined using the following formula: [(1x% cells intensity 1) 
+ (2x% cell intensity 2) + (3x% cells intensity 3)]. A cytoplasmic ‘H-Score’ was obtained in a 
similar way. As it was not possible to differentiate varying intensities of membrane staining, 
the percentage of any membrane positivity was scored i.e. a binary allocation of 1 
(membrane positive cells) or 0 (membrane negative cells) was allotted to the entire tumour 
within the whole mount tissue section. Following independent scoring of each case, the 
differences between each nuclear, cytoplasmic and membrane scores were evaluated. 
Where a difference in inter-scorer value for each subcellular location was ≥50, an average of 
the two scores was taken to produce a final score. Where two scores were >50 in difference, 
scorers agreed a consensus value on a multi-headed microscope. This gave a final nuclear, 
cytoplasmic and membrane score for each case. The total ANXA1 H-Score for each case 
was then determined using the final subcellular scores and was defined as (nuclear H-Score) 
+ (cytoplasmic H-Score) + (% membrane staining) to give a range of 0-700.    
 
Protein precipitation using trichloracetic acid (TCA) 
Cells were seeded in 6-well plates at a density of 300 000 cells per well. 48h later the 
supernatant of the cells was harvested and centrifuged for 5 min at 3000 rpm. Proteins 
present in the supernatant were precipitated using TCA as described previously. Briefly, one 
volume of 100% (w/v) TCA (Sigma-Aldrich, St. Louis, MO, USA) was added to 4 volumes of 
protein sample and incubated on ice for 30 min. Samples were centrifuged for 10 min at 
13200 rpm (4°C) and the pellet was washed twice with 500 µl ice-cold acetone. Afterwards, 
the pellet was dried for 5 min in a heat block (95°C), 45 µl 2x LSB was subsequently added 
and the pH was restored using 5 µl 1.5 M Tris, pH 8.8. 25 µl of the sample was analysed by 
immunoblotting. Additionally, the adherent cells were trypsinised, washed once with 1x PBS 
and a whole cell lysate was prepared. 40 µg of whole cell lysate was used for 
immunoblotting. 
 
Exosome isolation 
5x 106 HN5 Ctrl or ANXA1 knockdown cells were seeded in T75 flasks, in 10 ml medium per 
flask, 7 flasks each. The next day, cells were washed twice with 1x PBS and once with 
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DMEM w/o FCS. Finally, 10 ml DMEM including 10% bovine exo-free FBS (as well as 
pen/strep) were added to each flask. After 48h, the medium was centrifuged for 20 min at 
300xg followed by centrifugation at 2000xg for 20 min (both: 4°C). The supernatant was 
stored at -80°C until further analysis. The supernatant was thawed slowly over night at 4°C, 
centrifuged at 12200xg for 45 min (4°C), and then filtered with a 0.45 μm filter followed by 
ultracentrifugation (100,000xg for 2 h at 4°C). The exosome pellet was sequentially 
resuspended in sterile PBS and ultracentrifuged at 100,000xg for 90 min (4°C). After this 
washing step, the exosome pellet was resuspended in 200 μl sterile PBS and stored at -80°C 
until further analysis. 
 
Nanoparticle tracking analysis 
Exosome preparations which were stored at -80˚C were thawed slowly on ice. A 1:500 
dilution (in PBS) was prepared. Nanoparticle tracking analysis (NTA) is based on the 
principle that the rate of Brownian movement of nanoparticles in solution is a function of their 
size [41]. In this method, a laser beam is directed at a fixed angle to the vesicle suspension, 
and the side-scattered light is captured using a standard microscope and high-sensitivity 
camera. By tracking the Brownian movement of individual nanoparticles over time, a 
software (NTA 3.1, Malvern, Ltd) calculates their diameter given a known temperature and 
viscosity of the sample. One advantage of this method is the ability to measure size 
distribution in polydisperse samples. Exosome analysis was carried out as previously 
described [42]. Briefly, exosome preparations were diluted to a final volume of 1 ml of 0.45 
µm-filtered sterile PBS and examined using a Nanosight LM10-HS system fitted with a LM14 
laser unit-temperature module control (Malvern, Ltd) and with a syringe pump (Harvard 
Apparatus, Cat No 98-4730) at a constant flow injection of 60 A.U. Individual dilutions were 
standardised for each cell line and finally used at 1:100-1:200 of exosome preparation over 
PBS for optimal particle-per-frame performance of NTA. Five video recordings of 30 s each 
were captured using automatic laser intensity and camera level per individual sample. 
Tracking thresholding was manually adjusted for each sample and kept to a minimum value 
in order to ensure the tracking of all particles and to avoid noise-related artefacts. The videos 
were analysed and particle modal size and concentration was calculated. Each condition was 
repeated in 3 independent experiments. 
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Statistical analysis and software 
Statistical analysis of experimental data was performed using GraphPad Prism 6 software 
(Graphpad Software Inc., La Jolla, CA, USA) and data were compared using one-way 
ANOVA or unpaired student’s t-test. Data of at least 3 independent experiments is presented 
as mean +/- standard error of the mean (SEM) unless otherwise stated. p-Values less than 
0.05 were considered statistically significant. The bioinformatic results presented in this 
article were obtained using R version 3.3, Bioconductor version 3.3 and the software 
packages limma 3.28.6. 
 
 
Results 
ANXA1 is downregulated in HNSCC and this mediates an oncogenic phenotype 
We recently showed that ANXA1 is a direct target of the oncogenic microRNA miR-196a in 
HNSCC cell lines [3]. To determine ANXA1 expression levels in head and neck tumours, 
RNA Seq data of 504 tumour samples and 44 healthy controls was compared. ANXA1 
expression was found significantly downregulated in tumour samples (Figure 1A). 
Furthermore, there is a clear correlation between ANXA1 expression and tumour progression 
from G1 to G4. There is a decrease in ANXA1 in G2 compared to G1, with a further reduction 
in G3 (Figure 1B and Supplemental Table 1). To confirm the RNA Seq data, we evaluated 
ANXA1 protein expression by IHC in 41 oropharyngeal squamous cell carcinoma patient 
tissue samples. Intrasectional adjacent non-dysplastic surface and reticulated crypt 
epithelium consistently demonstrated high ANXA1 levels (mean total ANXA1 H score=455, 
median total ANXA1 H score=460; Figure 1C and D). By contrast ANXA1 protein levels were 
consistently decreased in the tumours when compared to intrasectional adjacent non-
dysplastic surface and reticulated crypt epithelium (p<0.0001, independent t-test, mean total 
ANXA1 H score=127, median total ANXA1 H score=80; Figure 1E, F and Supplemental 
Figure S1A and B as well as Figure 1G). Functional studies using shRNA to knockdown 
ANXA1 resulted in a clear increase in cellular proliferation in 4 different HNSCC cell lines 
(UTSCC-34 and USCC-22B Ctrl and ANXA1, Suppl. S2A and B; HN5 and HN30 Ctrl and 
ANXA1 knockdown cells, see Figure 1I). We also attempted to overexpress ANXA1 in 
HNSCC cell lines using various approaches. Although overexpression of the ANXA1 
construct increased ANXA1 protein levels in 293T cells and GFP as the transfection positive 
control in HNSCC cell lines was successful, we were unable to overexpress ANXA1 in 
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several HNSCC cell lines (see Suppl. S3A, B and C). This further supports a growth 
suppressor role for ANXA1 in HNSCC. 
Cleavage and secretion of ANXA1 have recently been reported [16, 43]. Extracellular ANXA1 
acts as ligand for the formyl peptide receptors FPR1 and FPR2 and receptor activation has 
been associated with increases in cellular proliferation and migration [44]. Immunoblot 
analysis of the HNSCC cell lines used in this study indicated expression of a shorter cleaved 
33 kDa version of ANXA1 in addition to the full-length 37 kDa protein (Figure 1H). 
Importantly, the 33 kDa, cleaved version of ANXA1 was also greatly diminished in the 
ANXA1 knockdown cell lines compared to vector control (Suppl. S4). Although expression of 
FPR2 was shown in HN5 and HSC3 by immunofluorescence analysis with MCF-7 cells 
serving as positive control (Suppl. S5), the HNSCC cell lines showed barely any secretion of 
ANXA1 into the supernatant (Suppl. S4). Addition of 100 nM recombinant ANXA1 to HN5 or 
HN30 ANXA1 knockdown and control also did not affect cellular proliferation rates (Figure 
1I). These findings argue against a role of FPR2 signalling and support a cell intrinsic effect 
of ANXA1 on cellular proliferation in HNSCC.  
 
ANXA1 regulates EGFR signalling 
Annexin A1 is mainly known for its anti-inflammatory activities, but has also been suggested 
to influence intracellular signalling pathways. When doing a literature-based network 
reconstruction using Metacore, a crosstalk between ANXA1 and EGFR signalling was 
observed (Figure 2A). EGFR is widely considered to be one of the central drivers of 
oncogenesis in HNSCC [23]. Head and neck tumour samples were immunohistochemically 
stained for ANXA1 and EGFR using either an antibody targeting the internal or external 
domain of the receptor (Figure 2B-E). Interestingly, an inverse relationship was observed for 
ANXA1 and EGFR staining. While ANXA1 expression is comparably high in the non-
dysplastic area, EGFR expression is low. In contrast to this, the tumour is characterised by 
high levels of EGFR and almost undetectable ANXA1 expression. Correlation analysis 
confirmed the trend towards an inverse correlation between (nuclear) ANXA1 and EGFR in 
the head and neck tumour samples analysed in this study. The correlation was seen for 2 
different antibodies targeting the external or internal domain of EGFR (adjusted r squared for 
EGFRexternal = 0.1869934 and for EGFRinternal = 0.1665316) (Suppl. Figure S6). Furthermore, 
ANXA1 knockdown indicated a change in the subcellular distribution of EGFR detected by 
Immunofluorescence: the staining pattern for EGFR in ANXA1 knockdown cells was more 
diffuse and there was a clear decrease in membraneous EGFR compared to control cells 
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(Figure 3A). This hints at increased activation and intracellular trafficking of EGFR in ANXA1 
knockdown cells. 
We then studied the response of the ANXA1 knockdown cells towards EGFR stimulation. 
When ANXA1 knockdown and control cells were incubated for 30 min in the presence of 50 
or 100 ng/ml recombinant EGF, there was an increase in EGFR tyrosine 1068 
phosphorylation in ANXA1 knockdown cells (Figure 3B). This increase in EGFR tyrosine 
1068 phosphorylation was stable over time and was maintained after 1 and 2h of receptor 
stimulation with 100 ng/ml recombinant EGF (Figure 3C). This indicates an increased and/or 
prolonged activation of EGFR receptor signalling in ANXA1 knockdown cells. EGFR 
signalling is known to control several different cellular signalling pathways such as PI3 
kinase/AKT, ERK and JAK/STAT signalling pathways [30]. Phosphorylation and activation of 
STAT3 and AKT was observed in the presence of recombinant EGF in both Ctrl and ANXA1 
knockdown cells. However, ANXA1 knockdown cells showed increased phosphorylation of 
AKT at serine 473 after receptor stimulation indicating increased activation of the PI3 
kinase/AKT pathway in these cells whereas STAT3 signalling via STAT3 phosphorylation 
was reduced (Figure 3D). Of note, increased phosphorylation of ERK1/2 was already 
observed in the absence of stimulus in ANXA1 knockdown cells which did not further 
increase in response to EGF treatment indicating EGF-independent ERK1/2 activation by 
ANXA1 downregulation. By contrast, control cells exhibited low baseline levels of 
phosphorylated ERK1/2 and phosphorylation was upregulated in the presence of 50 ng/ml 
recombinant EGF (Figure 3D). It has already been reported that EGF inhibits the growth of 
HN5 cells and can induce senescence [45]. We confirmed the inhibitory effect of EGF on wild 
type HN5 cells by MTT assay; however, ANXA1 knockdown HN5 cells had the tendency to 
show increased survival in the presence of 5 and 50 ng/ml recombinant EGF (Figure 3E) 
again suggesting a regulation of the EGFR pathway by ANXA1.  
Cetuximab, an IgG1 chimerized EGFR monoclonal antibody, binds with high affinity to the 
extracellular EGF domain of EGFR and thereby prevents ligand binding and receptor 
activation. ANXA1 knockdown and control cells were treated with increasing concentrations 
of cetuximab and cell viability was assessed by MTT assay. Interestingly, there was a trend 
towards increased cetuximab sensitivity in HN5 and HSC3 cells when ANXA1 was 
downregulated indicating a potential EGFR dependent response (Figure 3F). 
 
ANXA1 protein levels affect exosome production and the release of exosomal 
phospho-EGFR 
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Recent findings have demonstrated an important role of exosomal EGFR in metastasis 
formation. As ILVs can be precursors of exosomes, we speculated that ANXA1 may regulate 
exosomal EGFR release [35, 36]. Extracellular vesicles of HN5 Ctrl and ANXA1 knockdown 
cells were isolated by ultracentrifugation and characterized by nanoparticle tracking analysis. 
When measuring the concentration of particles per ml in relation to the diameter of the 
particles in nm, there was a difference in the distribution pattern of the particles between the 
HN5 Ctrl and ANXA1 knockdown cells (Figure 4A). Particles of HaCat cells which are known 
to secret high levels of exosomal EGFR served as positive control and the size of their 
exosomes peaked around 115 nm [46]. Interestingly, while exosomes of HN5 Ctrl cells 
showed a bimodal size distribution with peaks at approx. 115 nm and 140.5 nm, the peak at 
115 nm was lost in HN5 ANXA1 knockdown cells (Figure 4A). Combined with the 
observation that HN5 ANXA1 knockdown cells tended to produce lower levels of exosomes 
per ml (Figure 4B), this indicates a difference in exosome biogenesis and cargo release in 
ANXA1 modulated cells. To investigate this in more detail, the amount of exosomal 
phosphorylated EGFR in these cells was analysed by immunoblotting. Downregulation of 
ANXA1 resulted in reduced levels of exosomal phosphorylated EGFR (Figure 4C). This 
further supports an involvement of ANXA1 in cell-cell communication via exosomal EGFR. 
 
 
Discussion 
Current treatment strategies for head and neck cancer are surgery and radiotherapy alone or 
in combination with chemotherapy. These strategies are ineffective with up to 50% of 
patients relapsing, and are associated with significant morbidity [38]. This highlights the need 
for better predictive biomarkers and novel, more specific treatment approaches. We recently 
demonstrated a link between oncogenic miR-196a and poor treatment response in HNSCC 
patients. Further studies identified ANXA1 as a direct target of the oncogenic microRNA 
miR-196a potentially mediating therapy outcome [3]. In this study we demonstrate a tumour 
suppressor role of ANXA1 in HNSCC. ANXA1 was consistently downregulated in the 
analysed expression profiling data sets and its expression levels negatively correlated with 
the number of lymph nodes involved as well as the pathology stage N as shown by 
Spearman correlation test. Immunohistochemical staining of patient tumour samples 
detected substantially less ANXA1 in tumour samples compared to adjacent normal tissue. 
Overexpression of ANXA1 has been reported to have various growth inhibitory effects such 
as cell cycle arrest and/or apoptotic cell death in a range of cell lines through various 
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mechanisms [47-50]. We were unable to establish cell lines which transiently or stably 
overexpressed ANXA1 despite using various techniques. This suggests that the forced 
ANXA1 expression in HNSCC cell lines induces a selective cell survival disadvantage and 
consequently loss of the overexpressing clones. The results further support a tumour 
suppressive function of ANXA1 in HNSCC. 
The precise mechanism of ANXA1 downregulation in HNSCC remains currently unclear. As 
mentioned above we have found ANXA1 to be a target for downregulation by miR-196a in 
HNSCC. Although ANXA1 mutations are a rare event in HNSCC, one of the mutations 
reported (at amino acid position 122) is a nonsense mutation resulting in a truncated ANXA1 
(http://www.tumorportal.org/view?geneSymbol=ANXA1,https://hive.biochemistry.gwu.edu/cgi
-bin/prd/biomuta/servlet.cgi?gpageid=11&searchfield1=gene_name&searchvalue1=ANXA1).  
Additionally, chewing tobacco, which is one of the main risk factors of oral cancer, results in 
the loss of the anti-inflammatory activity of ANXA1 [20]. Collectively, these findings identify 
ANXA1 as a potential predictive and prognostic biomarker in HNSCC.  
We have previously demonstrated that ANXA1 knockdown in HNSCC cell lines induces 
increased tumour invasion and elevates expression of EMT markers [3]. ANXA1 is mainly an 
anti-inflammatory protein with important roles in the innate and adaptive immune response 
[7]. Inflammation has been shown to alter the tumour microenvironment as well as tumour 
immune responses and to induce tumour hypoxia [51, 52]. Additionally, hypoxia induces a 
chronic inflammatory state which further reduces immune responses within the tumour 
microenvironment [53, 54]. Considering the crucial role of ANXA1 in controlling inflammation, 
it would be important to investigate whether downregulation of ANXA1 in HNSCC results in 
increased tumour hypoxia and more aggressive disease as well as therapy resistance in 
HNSCC. This is particularly relevant as we initially identified miR-196a, which targets 
ANXA1, in HNSCC tumours with poor treatment outcome which is also a hallmark of more 
hypoxic cancers [3].  
ANXA1 seems to have both pro- or anti-proliferative activity depending on tumour types. 
Downregulation of ANXA1 in oropharyngeal cancer as well as other cancer subtypes has 
been described [15, 55-58]. Surprisingly, ANXA1 null mice show impaired tumour growth and 
specific subsets of breast cancers show upregulation of ANXA1 [17, 59]. The differences in 
ANXA1 activity could be determined by different subcellular locations, nuclear and 
membranous, and/or to its secreted and intracellular forms [13]. So far the tumour-associated 
functions of ANXA1 have been mainly linked to a paracrine/autocrine mechanism via 
secretion of ANXA1 and its interaction with its receptor FPR1 and/or 2 on the cell surface 
[60]. However, in this study no significant levels of the secreted form of ANXA1 were 
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detected in the HNSCC cell lines analysed. Our data therefore does not support a major 
contribution of extracellular ANXA1 and paracrine/autocrine signaling pathways in controlling 
cellular proliferation in HNSCC. The findings here suggest that the intracellular form of 
ANXA1 and its cell autonomous effects on intracellular signalling pathways may be important 
in regulating HNSCC tumour cell growth and invasion [3]. One candidate signalling pathway 
could be ERK1/2-mediated signalling as we detected constitutively high levels of 
phosphorylated ERK in the ANXA1 knockdown HNSCC cells as compared to control cells. 
Interestingly, He et al. recently showed that ANXA1 can decrease the nuclear accumulation 
of phosphorylated ERK, which leads to reduced expression of cyclin D1 and subsequent 
inhibition of proliferation of rat pulmonary arterial smooth muscle cells [48]. We also observed 
a decrease in STAT3 phosphorylation and thus STAT3 pathway activation in the absence of 
ANXA1. Changes in ANXA1 expression levels have already been reported to affect STAT3 
activation positively or negatively depending on the type of cancer. Silencing of another 
annexin superfamily member, Annexin A2, has additionally been associated with reduced 
EGF-induced STAT3 phosphorylation [61-63].  
ANXA1 has been reported to regulate EGFR-dependent signalling pathways [64]. 
Upregulation of EGFR and increased EGFR phosphorylation is the most common oncogenic 
event in HNSCC [65, 66]. Elevated EGFR expression as well as gene amplification has been 
shown to correlate with poor prognosis in HNSCC and a variety of other cancer types such 
as gastric, esophageal, lung and triple negative breast cancers [67-70]. Increased expression 
levels of EGFR correlate with chemo-resistance while lentiviral or siRNA mediated 
downregulation of EGFR expression has been reported to enhance chemo-sensitivity in 
HNSCC [71-73]. In recent years, multiple EGFR inhibitors have been developed, but cancer 
cells show select sensitivity to these drugs. The inherent and/or acquired resistance of 
cancers to EGFR inhibitors is unclear and is under intense investigation. Mutations in EGFR 
gene or changes in the subcellular localization of EGFR, resulting in inaccessibility of the 
inhibitor to the receptor, could be a contributing factor. However, most studies have focused 
on the cell autonomous EGFR regulation as a cause of treatment resistance. Interestingly, 
non-cell autonomous factors can also affect sensitivity towards EGFR-targeting drugs such 
as cetuximab. Van Dommelen et al. (2016), for example, reported an association between 
cetuximab response and extracellular vesicles [74]. It is known that EGFR signalling is highly 
regulated by intracellular trafficking and molecules involved in this process can affect EGFR 
signalling and EGFR localisation [32, 75]. To this end, Annexin A1 has shown to be required 
for the formation of ILVs in multivesicular bodies (MVBs) that sequester ligand-bound EGFR 
away from the limiting membrane [21]. In this study, we show that downregulation of ANXA1 
17 
 
resulted in increased and sustained phosphorylation of EGFR after EGF stimulation and that 
there was an inverse correlation between ANXA1 and EGFR expression levels in head and 
neck tumour samples. Interestingly, sustained phosphorylation of EGFR at tyrosine 1173, 
845 and/or 1068 has been reported to correlate with poor prognosis in HNSCC and high 
levels of EGFR phosphorylation facilitate metastasis in salivary gland carcinomas [76-78]. 
Downregulation of ANXA1 in combination with increased EGFR levels and EGFR-dependent 
signalling could therefore contribute to a malignant phenotype in HNSCC driving cancer 
progression and invasion. Our data suggest that one mechanism by which ANXA1 mediates 
its tumour suppressive activities in healthy cells is via ensuring ordered and timely 
degradation of phosphorylated EGFR and safeguarding regulated EGFR signalling pathway.  
Given the role of ANXA1 in ILV formation and the reports that ILVs are precursors of 
exosomes, we speculated that ANXA1 could also play a role in exosome production in 
addition to its role in EGFR signalling termination [33, 79]. Here, we observed a reduction in 
exosome production in HNSCC cell lines in response to ANXA1 knockdown. Interestingly, 
decreased levels of ANXA1 were also associated with disease progression. To our 
knowledge, this is one of the first reports which links disease progression and decreased 
activity of a potential tumour suppressor (ANXA1) with reduced exosome levels. So far 
malignant cells and disease progression have generally been associated with increased 
exosome production [46, 80]. Furthermore, our findings indicate that it is rather specific cargo 
and not general exosome levels that could be decisive for tumour progression. Along these 
lines, we see the disappearance of a subpopulation of exosomes in the analysed ANXA1 
knockdown cells and an accompanying decrease in the amount of exosomal 
phospho-EGFR. This hints at the existence of different exosome biogenesis pathways. 
ANXA1 might be responsible for the recruitment of phospho-EGFR into exosomes and this 
might be mediated by a (transient) interaction of ANXA1 and phospho-EGFR which has 
already been reported [33]. Exosomal EGFR has been linked to organ-specific metastasis by 
influencing premetastatic niche formation and to tumour immunity by inducing tolerance in 
recipient dendritic cells and as a consequence tumour antigen-specific regulatory T cells [36, 
37]. In summary, ANXA1 seems to be located at the interface of inflammation and cancer. 
The fact that cancer is considered as “wounds that do not heal” highlights the importance of 
balanced levels of anti-inflammatory proteins such as ANXA1 [81]. Future studies will be 
important to determine the impact of ANXA1-mediated reduction of exosomal 
phospho-EGFR on tumour microenvironment, hypoxia and tumour immunity.  
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Conclusion 
Our studies support a tumour suppressive function of ANXA1 in head and neck cancer. This 
role can mainly be attributed to the intracellular version of the protein. Intracellular ANXA1 
seems to exert its activities cell autonomously by affecting the strength and duration of 
EGFR-dependent signalling events but also by regulating exosomal phospho-EGFR release 
and thereby cell-cell communication. Further studies into the role of ANXA1 in exosome 
production in general and exosomal phospho-EGFR recruitment are required in order to fully 
elucidate the ANXA1/EGFR axis and its importance in HNSCC pathogenesis. 
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Figure legends 
Figure 1: 
ANXA1 is downregulated in head and neck cancer, which results in a more oncogenic 
phenotype in head and neck cancer independently of FPR2 signalling. 
1A: The FPKM levels of ANXA1 in healthy (n = 44) and tumour (n = 504) samples are shown 
as boxplots. Median and 25% and 75% quantiles is shown as box, 5% and 95% quantiles 
are visualized as whiskers and outliers are depicted as dots. Bar graphs are representing the 
-log10 adjusted p-values between tissues of the Cancer Genome Atlas. The p-value for the 
head and neck squamous cell carcinoma (HNSCC) is represented as a black bar. The 
number of samples used for the analysis for HNSC were in total 548 samples consisting of n 
Healthy= 44, n Tumour = 504 (p-value = 3.33e-12). 
1B: The clinical variable considering the tumour grade was used to analyze ANXA1 mRNA 
levels during tumour progression by boxplots. Median and 25% and 75% quantiles are 
shown as box, 5% and 95% quantiles are visualized as whiskers and outliers are depicted as 
dots. The number of samples used for the analysis of the tumour grades were in total 490 
samples consisting of n G1= 59, n G2= 295, n G3= 117, n G4= 2, n GX= 17. Tumour grades 
that were not identified were removed from the analysis. NS: p>0.05, *: p<0.05, **: p<0.01, 
***: p<0.001. 
1C/D/E/F: ANXA1 is consistently downregulated in head and neck cancer tissue samples. 
ANXA1 immunohistochemical expression is consistently high in normal oropharyngeal 
surface (C) and reticulated crypt (D) epithelium (scale bars = 100m). By contrast, ANXA1 is 
consistently downregulated in oropharyngeal squamous cell carcinoma (E: haematoxylin and 
eosin, F: ANXA1 immunoshistochemistry, scale bars = 200m). Carcinoma is outlined by 
black arrows and shown underlining normal surface epithelium. 
1G: Box and whisker plot of the H scores obtained for ANXA1 immunohistochemical staining 
of normal and head and neck cancer tissue samples. Median and 25% and 75% quantiles 
are shown as box, 5% and 95% quantiles are visualized as whiskers and outliers are 
depicted as dots. p<0.0001, independent t-test. 
1H: Expression of ANXA1 (full-length and cleaved) was assessed by immunoblotting in 
sh-scrambled Control (Ctrl) and sh-ANXA1 (KD1) transduced UTSCC6A, H357 and 
UTSCC34 cell lines. Tubulin served as loading control. The results of one exemplary 
immunoblot (n=3) are depicted. 
Figure Legends
1I: HN5 (left) and HN30 (right) Ctrl as well as ANXA1 KD1 cells were incubated in the 
absence or presence of 100 nM recombinant ANXA1 and cell proliferation was assessed 
daily by MTT assay over 5 days. The data represent mean +/- SEM of 3 independent 
experiments (n.s.: not significant; **: p≤0.01, ****: p≤0.0001, 2-way ANOVA). 
 
Figure 2: ANXA1 regulates EGFR signalling. 
2A: ANXA1 and EGFR network reconstruction based on the literature knowledge obtained 
from MetaCoreTM. 
2B/C/D/E: Representative photomicrograph of intracellular domain of EGFR (B: whole mount 
view, scale bar = 500m; C: medium power view, scale bar = 200m) and ANXA1 (D: whole 
mount view, scale bar = 500m; E: medium power view, scale bar = 200m) 
immunohistochemistry in the same head and neck squamous cell carcinoma tissue sample. 
Non-dysplastic surface epithelium is present at the top (B, D) and top right (C, E) while 
carcinoma is present in the lower part of each photomicrographs. Higher magnifications of B 
and D are shown in C and E, respectively. 
 
Figure 3: Downregulation of ANXA1 results in increased and prolonged activation of 
EGFR signalling. 
3A: HN5 Ctrl and ANXA1 KD1 cells were stained for total EGFR and DAPI was used as 
nuclear marker. Images were taken at 60x magnification. 
3B: HN5 Ctrl and ANXA1 KD1 cells were treated with different concentrations of recombinant 
EGF or 5% trehalose (Treh) as vehicle control for 30 min and the levels of total EGFR and 
EGFR phosphorylated on tyrosine 1068 were analysed by immunoblotting. Tubulin served as 
loading control. The results of one exemplary immunoblot (n=3) are depicted. 
3C: HN5 Ctrl and ANXA1 KD1 cells were incubated in the presence of 100 ng/ml 
recombinant EGF or 5% trehalose (Treh) as vehicle control for the indicated time points. 
Levels of total EGFR and EGFR phosphorylated on tyrosine 1068 were determined by 
immunoblotting. Tubulin was used as loading control. The results of one exemplary 
immunoblot (n=3) are depicted. 
 
3D: HN5 Ctrl and ANXA1 KD1 cells were incubated in the presence of 50 ng/ml recombinant 
EGF or 5% trehalose (Treh) as vehicle control for 1h. Levels of total STAT3, phosphorylated 
STAT3 (Tyr705), total AKT, phosphorylated AKT (Ser473), phosphorylated ERK1/2 as well 
as Annexin A1 were determined by immunoblotting. Tubulin served as loading control. The 
results of one exemplary immunoblot (n=3) are depicted. 
 
3E: HN5 Ctrl and ANXA1 KD1 cells were incubated in the presence of 0.5, 5 or 50 ng/ml 
recombinant EGF with daily medium change. Cell viability was assessed 4 days later by MTT 
assay. Data were normalized to vehicle control (trehalose) and the mean +/- SEM of 3 
independent experiments is shown (n.s.: not significant, 2-way ANOVA). 
3F: Cell viability of HN5 and HSC3 Ctrl as well as ANXA1 KD1 cells in the presence of 
increasing concentrations of cetuximab was assessed by MTT cell viability assay after the 
indicated time points. Data represent mean +/- SEM of 3 (HSC3) or 4 (HN5) independent 
experiments. Differences observed in cell viability between Ctrl and ANXA1 knockdown cells 
were statistically analysed and p-values are indicated (unpaired t-test; *: p<0.05, **: 
p=0.005). 
 
Figure 4: Downregulation of ANXA1 changes exosome production levels and 
exosomal phospho-EGFR content  
4A: Extracellular vesicles (EV) of HN5 Ctrl and ANXA1 KD1 as well as HaCat cell culture 
supernatants were isolated by ultracentrifugation and analysed by nanoparticle tracking 
analysis using Nanosight. The concentration of particles per ml was plotted against their bin 
centre in nm. Data represent mean +/- SEM of 3 independent experiments for HN5 Ctrl and 
ANXA1 KD1. 
4B: The overall concentration of isolated extracellular vesicles (EV) of HN5 Ctrl and ANXA1 
KD1 cell culture supernatants was determined in the course of nanoparticle tracking analysis 
using Nanosight. Data represent particles per ml and depict mean +/- SEM of 3 independent 
experiments (top; n.s.: not significant, unpaired t-test, p=0.4268). Video stills of exemplary 
measurements and of the vehicle control are shown below.  
4C: Levels of EGFR phosphorylated on tyrosine 1068 and CD63 in the extracellular vesicles 
of HN5 Ctrl and ANXA1 KD1 cells were determined by immunoblotting. The results of one 
exemplary immunoblot (n=3) are depicted. 
Figure legends for Suppl. Info 
 
Suppl. Table 1: Statistical analysis of Figure 1B covering all statistical combinations. 
Suppl. S1: ANXA1 is consistently downregulated in head and neck cancer tissue samples. 
A: Haematoxylin and eosin, B: ANXA1 immunohistochemistry of head and neck cancer 
tissue samples; scale bars = 20 m or 200 µm). Carcinoma is outlined by black arrows and 
shown underlining normal surface epithelium. 
Suppl. S2A/B: Ctrl and ANXA1 knockdown cell lines were generated using an Annexin A1 
targeting lentiviral construct (ANXA1 KD1). Knockdown of ANXA1 was confirmed by 
immunoblotting and the effect of ANXA1 knockdown on cell proliferation was assessed by 
daily counting. Modulated UTSCC34 (A) and UMSCC22B (B) cells were used for the 
analysis. The data represent mean +/- SEM (n=3); *: p≤0.01, multiple t-tests). 
Suppl. S3:  
A: 293T cells were transfected with empty vector (ev) or ANXA1 overexpression plasmid and 
overexpression of ANXA1 was analysed 48h after transfection by immunoblotting. Tubulin 
served as loading control. 
B/C: H357 (B) or HSC3 (C) cells were transiently transfected with empty vector (ev), ANXA1 
overexpression plasmid (ANXA1 OV) or GFP-expression plasmid (GFP). Cells were 
collected 14, 24 or 48h after transfection and expression of ANXA1 and GFP was analysed 
by immunoblotting. Tubulin was used as loading control. 
Suppl. S4: Intracellular and secreted levels of ANXA1 of HN5 and HSC3 Ctrl and ANXA1 
knockdown cells were analysed by immunoblotting. Whole cell lysates and TCA precipitates 
of conditioned cell culture medium were used. Tubulin was used to determine the purity of 
the cell culture supernatant. 
Suppl. S5: FPR2 expression was analysed by immunofluorescence in HN5 and HSC3 cells 
with MCF7 cells serving as positive control. Images were taken at 60x magnification.  
Suppl. S6: Correlation analysis between nuclear ANXA1 and EGFR (either stained for 
internal or external domain) in head and neck cancer samples stained 
immunohistochemically. Statistical analysis of the data is shown below. 
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Suppl. Fig S6 
Protein r.squared adj.r.squared sigma statistic p.value df logLik AIC BIC deviance df.residual
ANXA1_cyto 0.7 0.7 0.2 68.2 0.000 2.0 0.8 4.4 9.3 2.1 35.0
ANXA1_total 0.8 0.8 0.2 169.7 0.000 2.0 13.5 -20.9 -16.1 1.0 35.0
EGFR_ext 0.2 0.2 0.4 9.3 0.004 2.0 -14.9 35.7 40.6 4.8 35.0
EGFR_int 0.2 0.2 0.4 8.2 0.007 2.0 -15.3 36.7 41.5 5.0 35.0
totAnxa 0.9 0.9 0.1 250.6 0.000 2.0 19.6 -33.2 -28.4 0.8 35.0
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